Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer.
Taylor J, Kamat AM, Annapureddy D, Khene ZE, Howard J, Tan WS, McElree IM, Facundo D, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumiguié M, Lerner S, Black PC, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y, O'Donnell MA. Taylor J, et al. Among authors: o donnell ma. Eur Urol Oncol. 2024 Dec 17:S2588-9311(24)00288-8. doi: 10.1016/j.euo.2024.12.005. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39694798
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
Kamat AM, Lerner SP, O'Donnell M, Georgieva MV, Yang M, Inman BA, Kassouf W, Boorjian SA, Tyson MD, Kulkarni GS, Chang SS, Konety BR, Svatek RS, Balar A, Witjes JA. Kamat AM, et al. Eur Urol Oncol. 2020 Jun;3(3):318-340. doi: 10.1016/j.euo.2020.02.006. Epub 2020 Mar 20. Eur Urol Oncol. 2020. PMID: 32201133
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, Brausi M, Bree KK, Fernández MI, Guo CC, Horowitz A, Lamm DL, Lerner SP, Lotan Y, Mariappan P, McConkey D, Mertens LS, Mir C, Ross JS, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess PE, Svatek RS, Tan WS, Taoka R, Buckley R, Kamat AM. Li R, et al. Eur Urol. 2024 Dec;86(6):516-527. doi: 10.1016/j.eururo.2024.08.001. Epub 2024 Aug 24. Eur Urol. 2024. PMID: 39183090 Review.
Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.06.011.
Tan WS, O'Donnell M, Li R, Kamat AM, Packiam VT. Tan WS, et al. Eur Urol Oncol. 2023 Oct 26:S2588-9311(23)00225-0. doi: 10.1016/j.euo.2023.10.009. Online ahead of print. Eur Urol Oncol. 2023. PMID: 39492318 No abstract available.
245 results